Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Olverembatinib, and Prednisone for Ph+ B-ALL
NCT06754267Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, olverembatinib in B cell acute lymphoblastic leukemia (B-ALL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Dec 2024; status: recruiting.
02
Drugs
venetoclaxolverembatinib
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06754267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754267.